Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404857 | 1.00 | KDM4E (0.49) | KDM4ESLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL16398421 | 0.89 | KDM4E (0.47) | KDM4ESLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5408877 | 0.89 | KDM4E (0.47) | KDM4ESLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL4427570 | 0.82 | KDM4E (0.47) | KDM4ESLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL24063374 | 0.78 | KDM4E (0.44) | KDM4ESLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1052889 | 0.77 | CYP2C19 (0.39) | — | |
| SCHEMBL18304604 | 0.77 | CYP2C19 (0.39) | — | |
| SCHEMBL21531502 | 0.77 | CYP2C19 (0.39) | — | |
| SCHEMBL6398452 | 0.77 | HSP90AA1 (0.34) | KDM4ESLC6A2HTR2B | |
| SCHEMBL10535903 | 0.76 | SLC6A4 (0.43) | SLC6A4KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464861-B2 | Asymmetric addition reactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-11-05 | — | — | US | disclosed |
| US-10464861-B2 | Asymmetric addition reactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-11-05 | — | — | US | disclosed |
| EP-3307698-B1 | ASYMMETRIC ADDITION REACTIONS | UNIV OXFORD INNOVATION LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20180334414-A1 | ASYMMETRIC ADDITION REACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3307698-A1 | ASYMMETRIC ADDITION REACTIONS | Oxford University Innovation Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198836-A1 | ASYMMETRIC ADDITION REACTIONS | ISIS INNOVATION LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464861-B2 | Asymmetric addition reactions | CSPP1, CCRL2, CBR3 | KDM4E 3816/4885SLC6A4 3573/4885SLC6A2 3045/4885 |
| US-20180334414-A1 | ASYMMETRIC ADDITION REACTIONS | CSPP1, CCRL2, CBR3 | KDM4E 3816/4885SLC6A4 3573/4885SLC6A2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.